Please assess the completion status of the following clinical trial:

Trial Title: Bexarotene Augmentation of Antipsychotic Treatment for Chronic Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18-60 years, male or female~2. DSM-IV criteria for schizophrenia, or schizoaffective disorder.~3. Ability and willingness to sign informed consent for participation in the study~4. Stable blood parameters including adequate hematologic function, defined as WBC ≥ 4.300/μL, absolute neutrophil count ≥3.000/μL (\> 50%), and platelet count ≥ 180,000/μL; normal coagulation parameters; bilirubin ≤1.5 times the upper limit of normal (ULN); AST/ALT ≤ 2.5 × ULN; and serum creatinine ≤1.5 mg/dL.~5. Only patients who had a normal baseline fasting triglyceride (FTG) level will be entered into the study; triglycerides may be normalized before study entry with use of an antilipemic agent.~Exclusion Criteria:~1. Lipid abnormalities. Fasting triglyceride normal (normalization with an antilipemic allowed prior to study entry).~2. Leucopenia or neutropenia. Hematopoietic: Hemoglobin at least 12.5 g/dL; WBC\< 4300/μL; Absolute neutrophil count \< 3000/μL; Platelet count \< 155,000/μL~3. Evidence of organic brain damage, mental retardation, alcohol or drug abuse~4. Impairment of renal function~5. Hepatic dysfunction~6. A history of pancreatitis~7. Thyroid axis alterations~8. Suicide attempt in past year.~9. Cataracts.~10. Systemic treatment with more than 15,000 IU of vitamin A daily.~11. Patients with a known hypersensitivity to bexarotene or other components of the product.~12. Pregnant women or a woman who intends to become pregnant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Bexarotene (Targretin LGD1069) (Type: PLACEBO_COMPARATOR): None
- placebo (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).